FDA approves Celgene drug for multiple myelomaU.S. regulators have approved a new drug from Celgene Corp for patients with multiple myeloma whose disease has worsened after being treated with other cancer drugs.
"Multiple myeloma is a disease with a complex genetic basis," explains Professor Franzoso. "GADD45b is not expressed or 'switched on' in all myeloma cells, and so it's the best biomarker we have at the moment. In the future, we may also have other biomarkers which could help us to p...
A new three-drug combination has shown in a phase I/II clinical trial that it is a \"highly effective regimen\" in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute.doi:10.4161/...
Updated analysis of EMN02 demonstrated overall survival benefit to early ASCT for multiple myeloma Alfred L. Garfall CorrespondenceOpen Access03 Jan 2025Blood Cancer Journal Volume: 15, P: 1 TransTACs: novel heterobispecific antibodies for targeted protein degradation in cancer therapy ...
et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103, 1641–1646 (2004). CAS PubMed Google Scholar Kummer, C. et al. Multitracer positron emission tomographic imaging of exogenous gene expression ...
An update on drug combinations for treatment of myeloma. Multiple myeloma is the second most common haematological malignancy. It is becoming increasingly manageable with conventional and high-dose chemotherapy b... M Srikanth,FE Davies,GJ Morgan - 《Expert Opinion on Investigational Drugs》 被引量:...
Anti-BCMA novel therapies for multiple myeloma Abstract: Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals; however, the prognosis remains poor. The BCMA...MORE Vincenzo Sammartano , ... Alessandro Gozzetti ...
Janssen has submitted a new combination regimen for its blockbuster multiple myeloma drug Darzalex for approval with the FDA and EMA, hoping to give the treatment another edge over emerging competitors
Seventy-six FDA-approved oncology drugs and emerging therapeutics were evaluated in 25 multiple myeloma (MM) and 15 non-Hodgkin’s lymphoma cell lines and in 113 primary MM samples. Ex vivo drug sensitivities were mined for associations with clinical phe
but now new uses have been discovered for it using repurposing. Bupropion, which is generally used to treat depression, is now also used for smoking cessation and thalidomide, which was introduced for the treatment of morning sickness, is now recommended for multiple myeloma [2,6,7,8,9,10,...